Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:PLXP

PLx Pharma (PLXP) Stock Price, News & Analysis

PLx Pharma logo

About PLx Pharma Stock (NASDAQ:PLXP)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
3,000 shs
Average Volume
12.96 million shs
Market Capitalization
$603 thousand
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

PLx Pharma, Inc. is a late-stage specialty pharmaceutical company, which engages in the development and commercialization of technology platform for approved drugs. It offers PLxGuard delivery system, which uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs with a targeted release to select portions of the gastrointestinal (GI) tract. The company was founded by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Sparta, NJ.

Receive PLXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PLx Pharma and its competitors with MarketBeat's FREE daily newsletter.

PLXP Stock News Headlines

A grave, grave error.
President Donald Trump made headlines last month with a staggering claim. He stated that since taking office, more than $12 trillion in private investments into America have been “practically committed” on his watch. "Nobody's ever seen numbers like we have," he said, crediting his agenda of tariffs, tax cuts, and deregulation with making the difference. If true, the figure would indeed be astonishing – potentially tripling the roughly $4 trillion in gross private investment the US reported all of last year.
PLXp/USD - Pullix US Dollar
Protalix Biotherapeutics Inc (PLX)
Vertex Pharmaceuticals Inc VRTX
Vietnam National Petroleum Group (PLX)
PLx Pharma Inc (PLXPQ)
See More Headlines

PLXP Stock Analysis - Frequently Asked Questions

PLx Pharma Inc. (NASDAQ:PLXP) posted its quarterly earnings data on Friday, November, 12th. The biotechnology company reported ($0.37) EPS for the quarter, beating analysts' consensus estimates of ($0.46) by $0.09. The business's revenue for the quarter was up 560.0% on a year-over-year basis.

PLx Pharma (PLXP) raised $68 million in an initial public offering on Thursday, February 4th 2016. The company issued 3,800,000 shares at $17.00-$19.00 per share. Raymond James acted as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that PLx Pharma investors own include Sorrento Therapeutics (SRNE), Ford Motor (F), SCYNEXIS (SCYX), CymaBay Therapeutics (CBAY), Energy Transfer (ET), Meta Platforms (META) and Pfizer (PFE).

Company Calendar

Last Earnings
11/12/2021
Today
6/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PLXP
Employees
16
Year Founded
2002

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$46.13 million
Net Margins
-606.91%
Pretax Margin
-606.91%

Debt

Sales & Book Value

Annual Sales
$4.54 million
Price / Cash Flow
N/A
Book Value
$1.30 per share
Price / Book
N/A

Miscellaneous

Free Float
26,530,000
Market Cap
$603 thousand
Optionable
Not Optionable
Beta
3.79

Social Links

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:PLXP) was last updated on 6/22/2025 by MarketBeat.com Staff
From Our Partners